復(fù)旦大學(xué)附屬腫瘤醫(yī)院乳腺外科,復(fù)旦大學(xué)上海醫(yī)學(xué)院腫瘤學(xué)系,上海 200032
游離腹部皮瓣乳房重建的應(yīng)用及研究進(jìn)展
司 婧,吳 炅
復(fù)旦大學(xué)附屬腫瘤醫(yī)院乳腺外科,復(fù)旦大學(xué)上海醫(yī)學(xué)院腫瘤學(xué)系,上海 200032
吳 炅,主任醫(yī)師,教授,博士生導(dǎo)師?,F(xiàn)任復(fù)旦大學(xué)附屬腫瘤醫(yī)院乳腺外科主任醫(yī)師,復(fù)旦大學(xué)附屬腫瘤醫(yī)院副院長(zhǎng)。1993年畢業(yè)于原上海醫(yī)科大學(xué)(現(xiàn)復(fù)旦大學(xué)上海醫(yī)學(xué)院),1998年獲得腫瘤學(xué)博士學(xué)位?,F(xiàn)為中國(guó)抗癌協(xié)會(huì)乳腺癌專業(yè)委員會(huì)候任主任委員、上海市抗癌協(xié)會(huì)乳腺癌專業(yè)委員會(huì)主任委員、上海市醫(yī)學(xué)會(huì)腫瘤靶分子專科分會(huì)副主任委員。擅長(zhǎng)乳腺癌的綜合治療,特別是新的外科診療技術(shù)在乳腺疾病中的應(yīng)用,包括乳腺癌保乳手術(shù)、乳腺癌前哨淋巴結(jié)活檢、乳腺癌乳房重建手術(shù)等。曾獲國(guó)家科技進(jìn)步二等獎(jiǎng)、上海市科技進(jìn)步二等獎(jiǎng)和三等獎(jiǎng)等;獲上海市衛(wèi)生局首批“醫(yī)苑新星”、上海市衛(wèi)生局先進(jìn)工作者、復(fù)旦大學(xué)“世紀(jì)之星”、上海市科技啟明星等稱號(hào)。在研課題包括國(guó)家重點(diǎn)基礎(chǔ)研究發(fā)展計(jì)劃(973計(jì)劃)子課題、國(guó)家自然科學(xué)基金面上項(xiàng)目(2項(xiàng))、科技部對(duì)歐盟合作專項(xiàng)、上海市科委國(guó)際合作項(xiàng)目(政府間)、上海市科委國(guó)際合作項(xiàng)目等。目前發(fā)表論文250余篇,以第一作者、通信作者在SCI收錄期刊發(fā)表40余篇。參與撰寫專著多部。
乳腺癌發(fā)病率居女性新發(fā)惡性腫瘤的第一位,外科治療是重要的治療手段之一。全乳切除術(shù)后乳房重建能在不影響腫瘤學(xué)安全性的前提下,提高患者的生存質(zhì)量,其中,自體組織乳房重建因其特有的優(yōu)勢(shì)成為乳房重建的重要方式之一,而游離腹部皮瓣是自體組織乳房重建中最理想的材料。該研究將對(duì)游離腹部皮瓣乳房重建手術(shù)的臨床應(yīng)用、手術(shù)時(shí)機(jī)及并發(fā)癥進(jìn)行綜述,旨在探討游離腹部皮瓣乳房重建的應(yīng)用及研究進(jìn)展。
乳腺癌;乳房重建;游離腹部皮瓣
乳腺癌發(fā)病率居女性新發(fā)惡性腫瘤的第一位[1-2],外科手術(shù)是乳腺癌綜合治療中的重要手段之一。隨著人們對(duì)腫瘤生物學(xué)了解的不斷深入,乳腺癌治療理念及治療模式都在向“生物-心理-社會(huì)”方向轉(zhuǎn)變,因此,臨床醫(yī)師不僅要重視患者的腫瘤治療效果,同時(shí)要重視其術(shù)后生活質(zhì)量。在此背景下,乳腺癌患者全乳切除術(shù)后的乳房重建手術(shù)逐漸成為乳腺癌外科治療的重要補(bǔ)充,并在很大程度上提高了患者的生存質(zhì)量[3-5]。目前,臨床常用的乳房重建方式有自體組織重建、植入物重建和自體組織聯(lián)合植入物重建,其中,自體組織乳房重建因其具有自然的外觀及觸感、避免假體相關(guān)并發(fā)癥等優(yōu)勢(shì),成為乳房重建的重要方式之一。腹部皮瓣是自體組織乳房重建中最為理想的材料,腹壁下動(dòng)脈穿支(deep inferior epigastric perferator,DIEP)皮瓣技術(shù)是自體組織乳房重建的主要技術(shù)之一。本文將對(duì)游離腹部皮瓣乳房重建的臨床應(yīng)用及相關(guān)研究進(jìn)展進(jìn)行總結(jié)。
20世紀(jì)70年代,Schneider等[6]報(bào)道了背闊肌肌皮瓣乳房重建,開啟了應(yīng)用自體組織進(jìn)行乳房重建的先河。雖然背闊肌肌皮瓣乳房重建具有血管蒂解剖位置相對(duì)恒定、手術(shù)相對(duì)簡(jiǎn)單等優(yōu)勢(shì),成為許多醫(yī)師的首選術(shù)式,但其缺點(diǎn)也顯而易見:背闊肌肌皮瓣的組織量較小,組織皮瓣的皮島寬度有限,且肌肉組織會(huì)出現(xiàn)不同程度的廢用性萎縮,極大程度地限制了該皮瓣的廣泛應(yīng)用。
女性下腹部的皮膚及脂肪組織較為豐富,可隨體質(zhì)量的變化而改變,質(zhì)地柔軟,是自體組織乳房重建理想的修復(fù)工具。1979年Robbins[7]報(bào)道了縱型腹直肌肌皮瓣(vertical rectus abdominis myocutaneous, VRAM)乳房重建。1982年Hartrampf等[8]經(jīng)過改良報(bào)道了橫型腹直肌肌皮瓣(transverse rectus abdominis myocutaneous,TRAM)乳房重建,此后的一段時(shí)間,TRAM皮瓣技術(shù)成為自體組織乳房重建的主流技術(shù)。直至1989年,Koshima等[9]首次報(bào)道了從肌肉內(nèi)分離穿支血管、保留供區(qū)肌肉功能的穿支皮瓣技術(shù),顯著減少了TRAM皮瓣供區(qū)并發(fā)癥的發(fā)生情況,從此,乳房重建開始從肌皮瓣時(shí)代走向穿支皮瓣時(shí)代。1994年,DIEP皮瓣技術(shù)首次報(bào)道,成為目前乳腺癌治療中最為普及和可靠的顯微外科乳房重建技術(shù)[10-11]。
隨著乳房重建技術(shù)不斷發(fā)展,一些因各種原因無法使用腹部皮瓣,但又傾向于選擇自體組織乳房重建的乳腺癌患者,也可通過臀上、臀下、股前外側(cè)、股薄肌等皮瓣進(jìn)行乳房重建。這些皮瓣大多以穿支皮瓣的形式,通過與受區(qū)血管顯微吻合重建皮瓣血運(yùn)。
以往多項(xiàng)研究顯示,自體組織乳房重建不影響乳腺癌患者的腫瘤安全性,且能較大程度地提高患者的生存質(zhì)量,這為自體組織乳房重建的發(fā)展奠定了基礎(chǔ)[3-4,12-13]。近年來,自體組織乳房重建的應(yīng)用范圍在一定程度上得到了擴(kuò)展。一項(xiàng)隨訪10年的臨床研究顯示,局部進(jìn)展期乳腺癌患者接受游離TRAM皮瓣即刻乳房重建是安全可行的[14]。另外,一項(xiàng)隨訪12年的回顧性研究也顯示,對(duì)于炎性乳腺癌患者,全乳切除術(shù)后接受游離皮瓣乳房重建與未行乳房重建相比預(yù)后差異并無統(tǒng)計(jì)學(xué)意義,且重建后并發(fā)癥的發(fā)生率能夠得到較好的控制[15]。復(fù)旦大學(xué)附屬腫瘤醫(yī)院乳腺外科近15年的臨床資料顯示,在乳房重建患者中選擇自體組織重建的患者占88%,接受即刻或延期乳房重建的患者中選擇游離皮瓣重建的患者分別占19.2%及67.7%,且這一比例呈現(xiàn)上升趨勢(shì),特別在2010年之后,復(fù)旦大學(xué)附屬腫瘤醫(yī)院乳腺外科乳房重建帶蒂腹部皮瓣的應(yīng)用顯著減少,相對(duì)的,游離皮瓣的應(yīng)用迅猛增長(zhǎng)[16]。因此,游離皮瓣自體組織重建是目前乳房重建的發(fā)展趨勢(shì)。
目前,相比于帶蒂腹部皮瓣,乳房重建自體組織更傾向于選擇游離腹部皮瓣。經(jīng)典的TRAM皮瓣乳房重建以腹壁上動(dòng)脈為蒂,翻轉(zhuǎn)皮瓣后穿過皮下隧道到達(dá)受區(qū)以完成重建,由于手術(shù)受到血管蒂的限制,且蒂部含有腹直肌肌束,因此,乳房重建后往往會(huì)破壞部分乳房下皺襞和劍突區(qū)的形態(tài),皮瓣塑形效果欠佳。而游離腹部皮瓣以腹壁下動(dòng)脈為蒂,可以分離出較長(zhǎng)的血管蒂,在皮瓣塑形時(shí)有較大的自由度,術(shù)中患者可取坐位或半坐位,以對(duì)側(cè)乳房為參照精確控制皮瓣組織量,使再造乳房在對(duì)稱性、乳房下皺襞位置、乳房輪廓上均優(yōu)于TRAM皮瓣。特別對(duì)于健側(cè)乳房下垂的患者,游離腹部皮瓣能塑造豐滿的乳房下極,在美容效果上優(yōu)于帶蒂腹部皮瓣。
根據(jù)獲取腹直肌肌束的多少,游離腹部皮瓣可分為游離TRAM皮瓣、保留肌束的游離TRAM皮瓣、DIEP皮瓣和腹壁下淺動(dòng)脈(superficial inferior epigastric artery,SIEA)皮瓣。其中,保留肌束的游離TRAM皮瓣和DIEP皮瓣是乳房重建的首選,其優(yōu)勢(shì)在于保留了部分或全部的腹直肌及前鞘,減少了腹部供區(qū)的損傷,對(duì)腹壁功能實(shí)現(xiàn)了更大程度的保護(hù)。
游離腹部皮瓣乳房重建的臨床應(yīng)用需要充分的術(shù)前評(píng)估,包括患者全身健康狀況的評(píng)估和局部血管情況的評(píng)估。接受游離腹部皮瓣乳房重建的患者需要在術(shù)前排除腫瘤遠(yuǎn)處轉(zhuǎn)移及明顯的內(nèi)科合并癥,患者腹部組織量應(yīng)足夠,并可保證供區(qū)術(shù)后一期縫合。對(duì)于腹壁較為薄弱,存在或可能發(fā)生腹壁疝的患者,應(yīng)避免行此類手術(shù)。對(duì)于既往接受過腹部手術(shù),可能存在腹壁下血管、穿支血管或微血管網(wǎng)絡(luò)損傷的患者,可在術(shù)前運(yùn)用超聲、CT血管造影(CT angiography,CTA)或MR血管造影(MR angiography,MRA),對(duì)供區(qū)血管的情況進(jìn)行評(píng)估,以保障皮瓣的血供。其中,超聲對(duì)血管評(píng)估的準(zhǔn)確性較高,在了解血管軸向走行、鑒別動(dòng)靜脈等方面有其優(yōu)勢(shì),但超聲評(píng)估依賴于操作者的經(jīng)驗(yàn),較難獲得區(qū)域血管及其穿支的整體解剖學(xué)成像;CTA及MRA則可在短時(shí)間內(nèi)顯示腹壁下血管以及穿支血管的走行路徑,確定優(yōu)勢(shì)穿支的位置、數(shù)量及口徑,為臨床醫(yī)師術(shù)前預(yù)先選擇血管蒂帶來極大的便利[17-20]。已有多項(xiàng)研究對(duì)游離腹部皮瓣乳房重建術(shù)前行CTA或MRA對(duì)患者手術(shù)結(jié)局的影響進(jìn)行了報(bào)道,結(jié)果顯示,CTA或MRA的應(yīng)用可顯著降低皮瓣缺血壞死及供區(qū)相關(guān)并發(fā)癥的發(fā)生率,并且可以有效縮短手術(shù)時(shí)間,減少外科醫(yī)師術(shù)中的壓力[21-23]。通過上述血管影像學(xué)評(píng)估,外科醫(yī)師能更有針對(duì)性地解剖優(yōu)勢(shì)穿支血管,降低了手術(shù)的盲目性。
另外,肥胖、有吸煙史的患者,應(yīng)審慎考慮行游離腹部皮瓣乳房重建。研究顯示,與正常體質(zhì)量患者相比,肥胖患者發(fā)生皮瓣完全壞死、皮瓣血清腫、乳房皮膚壞死、腹壁疝、供區(qū)感染、供區(qū)血清腫的風(fēng)險(xiǎn)均有所升高,且其重建術(shù)后滿意度顯著低于正常體質(zhì)量患者[24-27]。與非吸煙患者相比,吸煙患者乳房皮膚壞死、腹部皮膚壞死和腹壁疝的發(fā)生率明顯升高[28-29]。因此,對(duì)于此類患者,應(yīng)在術(shù)前充分評(píng)估血管情況,術(shù)中獲取更多的血管穿支,增加皮瓣的血液灌注,減少相關(guān)并發(fā)癥的發(fā)生,保留肌束的游離TRAM皮瓣比DIEP皮瓣更為安全。
接受游離腹部皮瓣乳房重建的患者,在術(shù)前需要進(jìn)行皮瓣設(shè)計(jì),以保障皮瓣的血供,并獲得較好的對(duì)稱性?;颊呷≌玖⑽?,雙臂自然下垂,術(shù)者需在受區(qū)分別標(biāo)記胸骨中線、第二前肋、乳房下皺襞、乳房外側(cè)皺襞,界定出分離乳房皮瓣的范圍,提高乳房重建后的對(duì)稱性;供區(qū)取下腹部橫型皮瓣,皮瓣上界略高于臍孔水平,下界位于恥骨聯(lián)合上方,兩側(cè)可達(dá)髂前上棘上方、腋前線或腋中線。供區(qū)皮瓣的上下間距需考慮到縫合時(shí)的張力,手術(shù)醫(yī)師可在術(shù)前囑患者取屈曲位,預(yù)估上下切口間的張力,也可在術(shù)中沿供區(qū)皮瓣上界向上分離腹部皮瓣,將手術(shù)床調(diào)至屈曲位,下拉上腹部皮瓣以決定下界切口位置。另外,手術(shù)醫(yī)師需根據(jù)術(shù)前評(píng)估的優(yōu)勢(shì)穿支血管的位置,合理調(diào)整腹部皮瓣的設(shè)計(jì),使優(yōu)勢(shì)穿支盡量接近于皮瓣中間。
實(shí)施游離腹部皮瓣乳房重建的手術(shù)醫(yī)師需要對(duì)供區(qū)血管、受區(qū)血管的解剖及變異情況有充分的認(rèn)識(shí),并具備顯微血管吻合的能力。獲取供區(qū)皮瓣時(shí),需注意識(shí)別并分離腹壁下淺靜脈(super fi cial inferior epigastric vein,SIEV)和腹壁下淺動(dòng)脈(super fi cial inferior epigastric artery,SIEA),若SIEA口徑較粗,可考慮行SIEA皮瓣重建。術(shù)中保留SIEV非常重要,在完成吻合后靜脈引流不暢致皮瓣淤血的情況下,可將SIEV與受區(qū)其他靜脈進(jìn)行吻合,形成第二個(gè)靜脈回流。術(shù)者需評(píng)估腹直肌內(nèi)穿支血管的走向,以決定選擇何種游離腹部皮瓣,若一側(cè)腹直肌內(nèi)可見1~2支粗大的穿支,集中分布于內(nèi)側(cè)排或外側(cè)排,則非常適合DIEP的方式取瓣,若兩側(cè)均未發(fā)現(xiàn)較為粗大的穿支,或穿支血管在腹直肌內(nèi)走行于不同層次,則不必強(qiáng)求DIEP皮瓣,可將位于穿支血管間的肌肉及穿支周圍的少量腹直肌前鞘一起游離,獲得保留肌束的游離TRAM皮瓣。目前,較常選擇的受區(qū)血管為胸廓內(nèi)血管,術(shù)者可在術(shù)中觸摸肋間隙,選擇較寬、易于顯露、便于血管吻合的肋間隙,一般為第二或第三肋間隙,在所選定的肋間隙沿胸肌肌束走向?qū)⑿丶》珠_,再次評(píng)估從肋間肌穿出的穿支血管,判斷是否可作為受區(qū)血管,最后打開肋間肌,暴露內(nèi)乳血管,進(jìn)行顯微血管吻合[30-31]。若患者肋間隙較窄,顯微血管吻合存在一定困難,可切除所選肋間隙上方或下方的肋軟骨,使得血管暴露更為理想。通常,腹壁下深血管和內(nèi)乳血管的口徑比較一致,可采用端端吻合,吻合時(shí)需避免動(dòng)靜脈長(zhǎng)短不一,否則易導(dǎo)致靜脈成角卡壓,引起靜脈回流障礙。其中,靜脈血管壁薄,手工縫合難度大,可使用靜脈吻合器(Coupler),簡(jiǎn)化靜脈吻合過程。完成血管吻合后,術(shù)者可通過評(píng)估穿支血管的搏動(dòng)情況、皮瓣表面皮膚的顏色、毛細(xì)血管充盈時(shí)間等,判斷皮瓣再灌注后的循環(huán)狀態(tài)。
對(duì)于乳房體積較大、乳房下垂明顯的乳腺癌患者,游離腹部皮瓣乳房重建需要的組織量相對(duì)較多,往往需要保留Ⅲ區(qū)乃至部分Ⅳ區(qū)的皮瓣組織,因此,確保此類患者重建皮瓣的血供尤為重要。此時(shí),術(shù)者可考慮解剖雙側(cè)皮瓣穿支血管,尋找兩套受區(qū)血管進(jìn)行吻合,如胸廓內(nèi)血管的近心端(順向)和遠(yuǎn)心端(逆向),或除胸廓內(nèi)血管外,另取一套腋窩血管作為受區(qū)血管;也有文獻(xiàn)報(bào)道,可解剖雙側(cè)穿支血管或?qū)?cè)腹壁淺血管,先進(jìn)行對(duì)側(cè)腹壁深動(dòng)脈和(或)靜脈與供區(qū)側(cè)腹壁深血管分支的橋接,以增強(qiáng)對(duì)側(cè)皮瓣的血供,再將供區(qū)側(cè)穿支血管與受區(qū)血管進(jìn)行吻合[32-36]。另外,對(duì)于有腹部縱切口手術(shù)史的患者,也可用上述方法確保皮瓣血供[37]。
術(shù)者需根據(jù)健側(cè)乳房的大小及形態(tài)決定重建皮瓣放置的位置及方向,若健側(cè)乳房寬度較窄,但具有一定下垂度,則通常選擇縱向或斜向腋窩放置重建皮瓣,若健側(cè)乳房基底較寬,無明顯下垂,則可選擇橫向放置重建皮瓣。皮瓣塑形時(shí),患者需取坐位或半坐位,術(shù)者應(yīng)調(diào)整好乳房下皺襞的位置,并保證乳房上方及內(nèi)側(cè)的組織量,塑造自然的乳房外形。
游離腹部皮瓣乳房重建可分為即刻重建及延期重建,即刻重建適用于早期乳腺癌患者,一次全麻即可完成腫瘤原發(fā)灶的切除及乳房重建,應(yīng)用保留皮膚的全乳切除術(shù)(skin sparing mastectomy,SSM)或保留乳頭乳暈的全乳切除術(shù)(nipple sparing mastectomy,NSM),可使手術(shù)切口更為隱蔽,美容效果更好;延期重建適用于已接受全乳切除,尤其是曾接受輔助放療的患者,其美容效果稍遜于即刻重建。
影響乳房重建時(shí)機(jī)選擇的因素很多,除患者自身的人口學(xué)特征及乳腺癌的臨床病理特征外,輔助治療對(duì)重建時(shí)機(jī)的選擇有較大的影響,其中,又以輔助放療的影響最大。目前,接受全乳切除后放療(post-mastectomy radiotherapy,PMRT)的患者乳房重建的時(shí)機(jī)仍有爭(zhēng)議,有研究顯示,PMRT會(huì)增加即刻重建術(shù)后的并發(fā)癥,影響重建乳房的美容效果,也有文獻(xiàn)支持即刻乳房重建后行放療,認(rèn)為并不會(huì)對(duì)術(shù)后并發(fā)癥及患者滿意度產(chǎn)生顯著影響[38-40]。對(duì)于有術(shù)后放療計(jì)劃的患者,數(shù)項(xiàng)研究支持首選延期游離腹部皮瓣乳房重建,不僅避免了擴(kuò)張器或假體重建后的并發(fā)癥,還可將供區(qū)組織移植至放射野,替換經(jīng)過放射后的胸壁皮膚[41-43]。當(dāng)然,也有多項(xiàng)研究顯示,在有經(jīng)驗(yàn)的團(tuán)隊(duì)中,游離腹部皮瓣也可以用于即刻乳房重建,其對(duì)放療的耐受性優(yōu)于假體[44-45]。
自體乳房重建與假體重建不同,術(shù)者通過移植患者完好的自體組織進(jìn)行患側(cè)乳房形態(tài)的重塑,因此,受區(qū)和供區(qū)都可能發(fā)生相關(guān)的術(shù)后并發(fā)癥。
受區(qū)較為嚴(yán)重的并發(fā)癥為血管危象導(dǎo)致的皮瓣壞死,其中,靜脈危象的發(fā)生率高于動(dòng)脈危象,發(fā)生此類并發(fā)癥最常見的原因是顯微血管吻合過程中的技術(shù)問題[46]。靜脈危象發(fā)生的高峰時(shí)間為術(shù)后24~72 h,此時(shí),皮瓣的動(dòng)脈灌注往往沒有問題,而靜脈常因吻合口血栓、血管蒂成角、卡壓等機(jī)械性梗阻導(dǎo)致回流瘀滯,皮瓣可呈暗紫色并伴有皮瓣腫脹。若發(fā)生靜脈危象,筆者推薦先予以皮瓣減壓,再及時(shí)行手術(shù)探查,術(shù)中剪開吻合口,放出皮瓣內(nèi)淤血,并重新吻合靜脈,如有可能,可在受區(qū)再找一根靜脈,與皮瓣上的腹壁淺靜脈另行吻合。動(dòng)脈危象發(fā)生時(shí)間一般早于靜脈危象,原因主要為吻合技術(shù)不熟練,吻合血管口徑不一致,導(dǎo)致吻合過程中血管內(nèi)膜破壞、撕裂,造成血栓。動(dòng)脈危象往往出現(xiàn)皮瓣顏色蒼白,無毛細(xì)血管充盈反應(yīng),多普勒無法探及血管搏動(dòng),但由于上述現(xiàn)象往往發(fā)現(xiàn)較晚,解救以無效告終。筆者認(rèn)為,減少此類并發(fā)癥最好的方法是預(yù)防,預(yù)防勝于解救。術(shù)者必須全面掌握相關(guān)解剖學(xué)及顯微血管吻合知識(shí),手術(shù)技術(shù)過關(guān),并具有扎實(shí)的臨床判斷能力。術(shù)后需要??谱o(hù)理人員對(duì)皮瓣進(jìn)行監(jiān)測(cè),一旦發(fā)現(xiàn)危象,需及時(shí)通知醫(yī)師進(jìn)行探查。另外,一旦確認(rèn)皮瓣不能解救,應(yīng)盡早切除壞死皮瓣,尤其是靜脈瘀滯導(dǎo)致的皮瓣壞死,在動(dòng)脈沒有栓塞的情況下,患者會(huì)發(fā)生大量失血情況,甚至出現(xiàn)休克。
供區(qū)常見的嚴(yán)重并發(fā)癥為腹壁膨隆及腹壁疝,因此,關(guān)閉縫合供區(qū)切口時(shí),需采用可靠的無張力筋膜縫合[47-48]。供區(qū)應(yīng)用保留肌束的游離TRAM皮瓣及DIEP皮瓣時(shí),腹直肌前鞘破壞較少,特別是DIEP皮瓣,在最大程度上保留了腹直肌和前鞘,只要注意將鞘膜組織分層縫合,一般供區(qū)并發(fā)癥的發(fā)生率極低。接受游離TRAM皮瓣乳房重建的患者,可適當(dāng)運(yùn)用補(bǔ)片修復(fù)腹壁薄弱處,以降低此類并發(fā)癥的風(fēng)險(xiǎn)。研究顯示,肥胖、吸煙、有糖尿病病史等均為腹部切口愈合不良的高危因素[49-50]。因此,術(shù)者應(yīng)在術(shù)前仔細(xì)評(píng)估患者的合并疾病,在術(shù)中重視供區(qū)切口的分層減張縫合,預(yù)防此類并發(fā)癥的發(fā)生。
游離腹部皮瓣乳房重建是接受全乳切除乳腺癌患者重塑乳房形態(tài)的重要技術(shù)之一,不論與假體重建相比,還是與帶蒂皮瓣重建相比,其優(yōu)勢(shì)都相當(dāng)明顯,在具備顯微外科技術(shù)條件的醫(yī)療中心,游離腹部皮瓣乳房重建已成為乳房重建的常用方法,使大量患者從中受益。但是,這項(xiàng)技術(shù)需要一定的顯微外科基礎(chǔ),難度較高,學(xué)習(xí)周期較長(zhǎng),在應(yīng)用和推廣上存在較大阻力。目前,國(guó)內(nèi)有資質(zhì)的中心正積極開展再教育項(xiàng)目,教授相關(guān)技術(shù),分享臨床經(jīng)驗(yàn)。相信隨著??婆嘤?xùn)的不斷加強(qiáng),患者對(duì)自體組織重建認(rèn)識(shí)的加深,游離腹部皮瓣乳房重建手術(shù)一定能為更多乳腺癌患者帶來生活質(zhì)量的獲益。
[1] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29.
[3] ELTAHIR Y, WERNERS L L, DREISE M M, et al. Quality-of-life outcomes between mastectomy alone and breast reconstruction: comparison of patient-reported BREAST-Q and other health-related quality-of-life measures[J]. Plast Reconstr Surg, 2013, 132(2): 201e-209e.
[4] NG S K, HARE R M, KUANG R J, et al. Breast reconstruction post mastectomy: patient satisfaction and decision making[J]. Ann Plast Surg, 2016, 76(6): 640-644.
[5] HOWES B H, WATSON D I, XU C, et al. Quality of life following total mastectomy with and without reconstruction versus breast-conserving surgery for breast cancer: Acase-controlled cohort study[J]. J Plast Reconstr Aesthet Surg, 2016, 69(9): 1184-1191.
[6] SCHNEIDER W J, HILL H J, BROWN R G. Latissimus dorsi myocutaneous fl ap for breast reconstruction[J]. Br J Plast Surg, 1977, 30(4): 277-281.
[7] ROBBINS T H. Rectus abdominis myocutaneous flap for breast reconstruction[J]. Aust N Z J Surg, 1979, 49(5): 527-530.
[8] HARTRAMPF C R, SCHEFLAN M, BLACK P W. Breast reconstruction with a transverse abdominal island fl ap[J]. Plast Reconstr Surg, 1982, 69(2): 216-225.
[9] KOSHIMA I, SOEDA S. Inferior epigastric artery skin fl aps without rectus abdominis muscle[J]. Br J Plast Surg, 1989, 42(6): 645-648.
[10] ALLEN R J, TREECE P. Deep inferior epigastric perforator flap for breast reconstruction[J]. Ann Plast Surg, 1994, 32(1): 32-38.
[11] HEALY C, ALLEN R S. The evolution of perforator flap breast reconstruction: twenty years after the fi rst DIEP fl ap[J]. J Reconstr Microsurg, 2014, 30(2): 121-125.
[12] PLATT J, BAXTER N N, MCLAUGHLIN J, et al. Does breast reconstruction after mastectomy for breast cancer affect overall survival? Long-term follow-up of a retrospective population-based cohort[J]. Plast Reconstr Surg, 2015, 135(3): 468e-476e.
[13] van MIERLO D R, LOPEZ P T, SCHIPPER R J, et al. No increase of local recurrence rate in breast cancer patients treated with skin-sparing mastectomy followed by immediate breast reconstruction[J]. Breast, 2013, 22(6): 1166-1170.
[14] CRISERA C A, CHANG E I, DA L A, et al. Immediate free flap reconstruction for advanced-stage breast cancer: is it safe?[J]. Plast Reconstr Surg, 2011, 128(1): 32-41.
[15] CHANG E I, CHANG E I, ITO R, et al. Challenging a traditional paradigm: 12-year experience with autologous free flap breast reconstruction for inflammatory breast cancer[J]. Plast Reconstr Surg, 2015, 135(2): 262e-269e.
[16] CHEN J J, HUANG N S, XUE J Y, et al. Current status of breast reconstruction in Southern China: a 15 year, single institutional experience of 20 551 breast cancer patients[J]. Medicine (Baltimore), 2015, 94(34): e1399.
[17] MATHES D W, NELIGAN P C. Current techniques in preoperative imaging for abdomen-based perforator fl ap microsurgical breast reconstruction[J]. J Reconstr Microsurg, 2010, 26(1): 3-10.
[18] PIORKOWSKI J R, DEROSIER L C, NICKERSON P, et al. Preoperative computed tomography angiogram to predict patients with favorable anatomy for super fi cial inferior epigastric artery fl ap breast reconstruction[J]. Ann Plast Surg, 2011, 66(5): 534-536.
[19] NAHABEDIAN M Y. Overview of perforator imaging and flap perfusion technologies[J]. Clin Plast Surg, 2011, 38(2): 165-174.
[20] AGRAWAL M D, THIMMAPPA N D, VASILE J V, et al. Autologous breast reconstruction: preoperative magnetic resonance angiography for perforator fl ap vessel mapping[J]. J Reconstr Microsurg, 2015, 31(1): 1-11.
[21] SCHAVERIEN M V, LUDMAN C N, NEIL-DWYER J, et al. Contrast-enhanced magnetic resonance angiography for preoperative imaging in DIEP fl ap breast reconstruction[J]. Plast Reconstr Surg, 2011, 128(1): 56-62.
[22] CASEY W R, REBECCA A M, KREYMERMAN P A, et al. Computed tomographic angiography: assessing outcomes[J]. Clin Plast Surg, 2011, 38(2): 241-252.
[23] ROZEN W M, ANAVEKAR N S, ASHTON M W, et al. Does the preoperative imaging of perforators with CT angiography improve operative outcomes in breast reconstruction?[J]. Microsurgery, 2008, 28(7): 516-523.
[24] SINHA S, RUSKIN O, D’ANGELO A, et al. Are overweight and obese patients who receive autologous free- fl ap breast reconstruction satisfied with their postoperative outcome? A single-centre study[J]. J Plast Reconstr Aesthet Surg, 2016, 69(1): 30-36.
[25] WANG X L, LIU L B, SONG F M, et al. Meta-analysis of the safety and factors contributing to complications of MSTRAM, DIEP, and SIEA fl aps for breast reconstruction[J]. Aesthetic Plast Surg, 2014, 38(4): 681-691.
[26] LARSON K E, OZTURK C N, KUNDU N, et al. Achieving patient satisfaction in abdominally based free flap breast reconstruction: correlation with body mass index subgroups and weight loss[J]. Plast Reconstr Surg, 2014, 133(4): 763-773.
[27] CHANG D W, WANG B, ROBB G L, et al. E ff ect of obesity on fl ap and donor-site complications in free transverse rectus abdominis myocutaneous flap breast reconstruction[J]. Plast Reconstr Surg, 2000, 105(5): 1640-1648.
[28] KLASSON S, NYMAN J, SVENSSON H, et al. Smoking increases donor site complications in breast reconstruction with DIEP fl ap[J]. J Plast Surg Hand Surg, 2016, 50(6): 331-335.
[29] CHANG D W, REECE G P, WANG B, et al. E ff ect of smoking on complications in patients undergoing free TRAM fl ap breast reconstruction[J]. Plast Reconstr Surg, 2000, 105(7): 2374-2380.
[30] SAINT-CYR M, YOUSSEF A, BAE H W, et al. Changing trends in recipient vessel selection for microvascular autologous breast reconstruction: an analysis of 1 483 consecutive cases[J]. Plast Reconstr Surg, 2007, 119(7): 1993-2000.
[31] SAINT-CYR M, CHANG D W, ROBB G L, et al. Internal mammary perforator recipient vessels for breast reconstruction using free TRAM, DIEP, and SIEA flaps[J]. Plast Reconstr Surg, 2007, 120(7): 1769-1773.
[32] HERNANDEZ R J, SHERIF R D, TORINA P J, et al. Use of both antegrade and retrograde internal mammary vessels in the bipedicled deep inferior epigastric perforator fl ap for uni-lateral breast reconstruction[J]. J Plast Reconstr Aesthet Surg, 2017,70(1):47-53.
[33] CHANG E I, KRONOWITZ S J. Dual-pedicle fl ap for unilateral autologous breast reconstruction revisited: evolution and optimization of flap design over 15 years[J]. Plast Reconstr Surg, 2016, 137(5): 1372-1380.
[34] XU H, DONG J, WANG T. Bipedicle deep inferior epigastric perforator fl ap for unilateral breast reconstruction: seven years’ experience[J]. Plast Reconstr Surg, 2009, 124(6): 1797-1807.
[35] KOOLEN P G, LEE B T, LIN S J, et al. Bipedicle-conjoined perforator flaps in breast reconstruction[J]. J Surg Res, 2015, 197(2): 256-264.
[36] GALANIS C, NGUYEN P, KOH J, et al. Microvascular lifeboats: a stepwise approach to intraoperative venous congestion in DIEP fl ap breast reconstruction[J]. Plast Reconstr Surg, 2014,134(1): 20-27.
[37] CHANG C C, HUANG J J, WU C W, et al. A strategic approach for DIEP fl ap breast reconstruction in patients with a vertical midline abdominal scar[J]. Ann Plast Surg, 2014, 73(Suppl 1): 6-11.
[38] MIRZABEIGI M N, SMARTT J M, NELSON J A, et al. An assessment of the risks and bene fi ts of immediate autologous breast reconstruction in patients undergoing postmastectomy radiation therapy[J]. Ann Plast Surg, 2013, 71(2): 149-155.
[39] TAGHIZADEH R, MOUSTAKI M, HARRIS S, et al. Does post-mastectomy radiotherapy a ff ect the outcome and prevalence of complications in immediate DIEP breast reconstruction? A prospective cohort study[J]. J Plast Reconstr Aesthet Surg, 2015, 68(10): 1379-1385.
[40] CHANG E I, LIU T S, FESTEKJIAN J H, et al. E ff ects of radiation therapy for breast cancer based on type of free fl ap reconstruction[J]. Plast Reconstr Surg, 2013, 131(1): 1e-8e.
[41] BAUMANN D P, CROSBY M A, SELBER J C, et al. Optimal timing of delayed free lower abdominal flap breast reconstruction after postmastectomy radiation therapy[J]. Plast Reconstr Surg, 2011, 127(3): 1100-1106.
[42] LEVINE S M, PATEL N, DISA J J. Outcomes of delayed abdominal-based autologous reconstruction versus latissimus dorsi fl ap plus implant reconstruction in previously irradiated patients[J]. Ann Plast Surg, 2012, 69(4): 380-382.
[43] HANSON S E, SMITH B D, LIU J, et al. Fewer revisions in abdominal-based free flaps than latissimus dorsi breast reconstruction after radiation[J]. Plast Reconstr Surg Glob Open, 2016, 4(9): e866.
[44] TAGHIZADEH R, MOUSTAKI M, HARRIS S, et al. Does post-mastectomy radiotherapy a ff ect the outcome and prevalence of complications in immediate DIEP breast reconstruction? A prospective cohort study[J]. J Plast Reconstr Aesthet Surg, 2015, 68(10): 1379-1385.
[45] CLARKE-PEARSON E M, CHADHA M, DAYAN E, et al. Comparison of irradiated versus nonirradiated DIEP fl aps in patients undergoing immediate bilateral DIEP reconstruction with unilateral postmastectomy radiation therapy (PMRT)[J]. Ann Plast Surg, 2013, 71(3): 250-254.
[46] FOSNOT J, JANDALI S, LOW D W, et al. Closer to an understanding of fate: the role of vascular complications in free fl ap breast reconstruction[J]. Plast Reconstr Surg, 2011, 128(4): 835-843.
[47] BAJAJ A K, CHEVRAY P M, CHANG D W. Comparison of donor-site complications and functional outcomes in free muscle-sparing TRAM fl ap and free DIEP fl ap breast reconstruction[J]. Plast Reconstr Surg, 2006, 117(3): 737-746, 747-750.
[48] EGEBERG A, RASMUSSEN M K, SORENSEN J A. Comparing the donor-site morbidity using DIEP, SIEA or MSTRAM fl aps for breast reconstructive surgery: a meta-analysis[J]. J Plast Reconstr Aesthet Surg, 2012, 65(11): 1474-1480.
[49] WANG X L, LIU L B, SONG F M, et al. Meta-analysis of the safety and factors contributing to complications of MSTRAM, DIEP, and SIEA fl aps for breast reconstruction[J]. Aesthetic Plast Surg, 2014, 38(4): 681-691.
[50] CHANG E I, CHANG E I, SOTO-MIRANDA M A, et al. Evolution of bilateral free flap breast reconstruction over 10 years: optimizing outcomes and comparison to unilateral reconstruction[J]. Plast Reconstr Surg, 2015, 135(6): 946e-953e.
Research progress and application of breast reconstruction with free abdominal flap
SI Jing, WU Jiong
(Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China)
Breast cancer is the most common malignant tumor in women. Surgical treatment is one of the important treatment methods. Breast reconstruction following mastectomy can improve patients’ quality of life with acceptable oncological safety. Autologous tissue breast reconstruction has become an important way owing to its speci fi c advantages. The ideal tissue for autologous breast reconstruction is free abdominal fl ap. This review presented the clinical application, timing of operation and complications of breast reconstruction with free abdominal fl ap.
Breast cancer; Breast reconstruction; Free abdominal fl ap
WU Jiong E-mail: wujiong1122@vip.sina.com
10.19401/j.cnki.1007-3639.2017.08.001
R737.9
A
1007-3639(2017)08-0601-07
2017-02-25)
吳 炅 E-mail: wujiong1122@vip.sina.com